Heart Failure in Patients With Diabetes: Cells, Crosstalk and Consequences
Launched by UNIVERSITY OF LEEDS · Jan 8, 2025
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, titled "Heart Failure in Patients With Diabetes: Cells, Crosstalk and Consequences," aims to understand how diabetes and heart failure affect the body differently. Researchers will study 600 participants, including those with heart failure and diabetes, those with only one of these conditions, and some who have neither. By looking closely at various body tissues, such as fat and muscle, and using special tests like heart scans and blood tests, the team hopes to gather important information about how these conditions interact and impact overall health.
To join the study, participants must be over 18 years old and able to provide consent. They should also be mentally competent to follow the study's instructions. However, certain individuals, like those with severe health issues or pregnant women, will not be eligible. Participants can expect to undergo various tests and evaluations, which will help the researchers create a detailed understanding of how diabetes and heart failure work together. This knowledge could lead to better treatments and care for people dealing with these conditions in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age \>18 years
- • Ability to provide written informed consent
- • Persons who are legally competent and mentally able to follow the instructions of the study staff
- Exclusion Criteria:
- • Anaemia Hb \<8 mg/dl
- • Patients with acute infectious diseases (e.g. pneumonia)
- • Patients with heart failure due to sepsis
- • People with acute myocardial ischemia, which is manifested, for example, by angina pectoris or ECG changes under stress
- • Patients with acute liver or kidney failure or severe COPD (FEV1\<1.0)
- • Pregnant and breastfeeding women
- • People who are institutionalized on official or court orders
- • People who are dependent or employed by the sponsor or investigator
- • Taking study medication (of an investigational drug) 30 days before the start of the study
About University Of Leeds
The University of Leeds is a prestigious research institution located in the United Kingdom, renowned for its commitment to advancing knowledge through innovative research and education. As a clinical trial sponsor, the University of Leeds leverages its diverse expertise and collaborative environment to facilitate high-quality clinical studies that aim to improve health outcomes and contribute to the scientific community. The university fosters interdisciplinary partnerships, ensuring rigorous methodologies and ethical standards in its research initiatives. By integrating cutting-edge technologies and a patient-centered approach, the University of Leeds plays a vital role in translating research findings into practical applications for healthcare improvement.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Leeds, West Yorkshire, United Kingdom
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported